UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis

Cell, 2012-06, Vol.149 (7), p.1536-1548

2012

Volltextzugriff (PDF)

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism

Cancer cell, 2018-11, Vol.34 (5), p.807-822.e7

2018

Volltextzugriff (PDF)

Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma

Molecular cancer therapeutics, 2023-01, Vol.22 (1), p.123-134

2023

Volltextzugriff (PDF)

An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance

Genes & development, 2011-08, Vol.25 (15), p.1628-1640

2011

Volltextzugriff (PDF)

Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma

Molecular cancer therapeutics, 2023-04, Vol.22 (4), p.539-550

2023

Volltextzugriff (PDF)

The mitochondrial p53 pathway

Biochimica et biophysica acta, 2009-05, Vol.1787 (5), p.414-420

2009

Volltextzugriff (PDF)

Radiosensitization of Epidermal Growth Factor Receptor/HER2–Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status

Clinical cancer research, 2010-02, Vol.16 (3), p.912-923

2010

Volltextzugriff (PDF)

Targeting RAS in pediatric cancer: is it becoming a reality?

Current opinion in pediatrics, 2020-02, Vol.32 (1), p.48

2020

Volltextzugriff (PDF)

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma

Oncogene, 2022-05, Vol.41 (21), p.2973-2983

2022

Volltextzugriff (PDF)

SNAI2-Mediated Repression of BIM Protects Rhabdomyosarcoma from Ionizing Radiation

Cancer research (Chicago, Ill.), 2021-11, Vol.81 (21), p.5451-5463

2021

Volltextzugriff (PDF)

Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies

Science signaling, 2017-09, Vol.10 (498)

2017

Volltextzugriff (PDF)

Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma

Molecular cancer therapeutics, 2022-01, Vol.21 (1), p.170-183

2022

Volltextzugriff (PDF)

Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRAS Q61X Mutant Rhabdomyosarcoma

Molecular cancer therapeutics, 2022-01, Vol.21 (1), p.170-183

2022

Volltextzugriff (PDF)

Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (10), p.2109-2119

2015

Volltextzugriff (PDF)

Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274

Cancer letters, 2010-03, Vol.289 (2), p.228-236

2010

Volltextzugriff (PDF)

Identification of p53 in mitochondria

Methods in molecular biology (Clifton, N.J.), 2013, Vol.962, p.75

2013

Volltextzugriff (PDF)

Negative feedback at the level of nuclear receptor coregulation. Self-limitation of retinoid signaling by RIP140

The Journal of biological chemistry, 2003-11, Vol.278 (45), p.43889-43892

2003

Volltextzugriff (PDF)

Repression of cyclin D1 as a target for germ cell tumors

International journal of oncology, 2007-02, Vol.30 (2), p.333-340

2007

Volltextzugriff (PDF)

Abstract A54: Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma

Cancer research (Chicago, Ill.), 2020-07, Vol.80 (14_Supplement), p.A54-A54

2020

Volltextzugriff (PDF)

Abstract B13: Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma

Molecular cancer research, 2020-05, Vol.18 (5_Supplement), p.B13-B13

2020

Volltextzugriff (PDF)

Abstract 4458: Regulation of MYC protein stability by mutant KRAS in pancreatic ductal adenocarcinoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4458-4458

2017

Volltextzugriff (PDF)

Negative Feedback at the Level of Nuclear Receptor Coregulation

The Journal of biological chemistry, 2003-11, Vol.278 (45), p.43889-43892

2003

Volltextzugriff (PDF)

Abstract IA023: Therapeutic efficacy of trametinib and ganitumab in RAS-mutated rhabdomyosarcoma

Clinical cancer research, 2022-09, Vol.28 (18_Supplement), p.IA023-IA023

2022

Volltextzugriff (PDF)

An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance

Genes & development, 2011-09, Vol.25 (18), p.1997-1997

2011

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Humans
(16)
Animals
(11)
Oncology
(10)
Mice
(9)
Cell Line, Tumor
(8)
Cell Biology
(7)
Apoptosis
(5)
Biochemistry & Molecular Biology
(5)
Mutation
(5)
Child
(4)
Rhabdomyosarcoma - Genetics
(4)
Tumors
(4)
Cell Differentiation
(3)
Female
(3)
Gene Expression Regulation, Neoplastic
(3)
Genes, Ras
(3)
Genetics & Heredity
(3)
Mice, Scid
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism

Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma

An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance

Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma

The mitochondrial p53 pathway

Radiosensitization of Epidermal Growth Factor Receptor/HER2–Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status

Targeting RAS in pediatric cancer: is it becoming a reality?

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma

SNAI2-Mediated Repression of BIM Protects Rhabdomyosarcoma from Ionizing Radiation

Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies

The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models

Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma

Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRAS Q61X Mutant Rhabdomyosarcoma

Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms

Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274

Identification of p53 in mitochondria

Negative feedback at the level of nuclear receptor coregulation. Self-limitation of retinoid signaling by RIP140

Repression of cyclin D1 as a target for germ cell tumors

Abstract A54: Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma

Abstract B13: Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma

Abstract 4458: Regulation of MYC protein stability by mutant KRAS in pancreatic ductal adenocarcinoma

Negative Feedback at the Level of Nuclear Receptor Coregulation

Abstract IA023: Therapeutic efficacy of trametinib and ganitumab in RAS-mutated rhabdomyosarcoma

An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance

Suchergebnisse filtern